All In MedTech

Device Trial Radar · NCT06992089

SHort Of Pace - Heart Failure (SHOP-HF)

Pacemaker Implantation in Patients With Heart Failure With Preserved Ejection Fraction, Chronotropic Incompetence and Small Ventricular Volume. The SHOP-HF Trial

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Jun 17, 2025

Primary completion

Jun 2027

Study completion Jun 2027

Sponsor

Sponsor type
Academic, hospital or other
First posted
May 28, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Crossover
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed as a multicenter, prospective, controlled, randomized, two-arms, cross-over, two parallel cohorts, efficacy Clinical research with CE-marked medical device . The crossover trial will be performed in a blind fashion, so each participant will be evaluated during both blinded pacing-on and pacing-off phases, each of which will last 3 months. The population includes patients with the diagnosis of stable HFpEF according to criteria of the European Society of Cardiology and New York Heart Association (NYHA) functional class II-III/IV, left ventricular hypertrophy with small ventricular volume, sinus rhythm with low basal heart rate and chronotropic incompetence (CI). All patients will undergo pacemaker implantation, and computer-generated randomization sequence previously designed will be used to allocate participants (in a 1:1 ratio) to receive: (a) programming of the pacemaker with pacing On followed by pacing Off in two periods of 3 months; or (b) programming of the pacemaker with pacing Off followed by pacing On in two periods of 3 months. The study will be conducted in three centers in Spain. Discounting the time due to staggered entry, the total duration of a patient's follow-up will be 7 months.

Conditions

  • Heart Failure With Preserved Ejection Fraction

Interventions

  • Dual-chamber cardiac pacemaker (Proponent MRI L211/L231 or Accolade MRI L311/L331, Boston Scientific), single-chamber cardiac pacemaker (Essentio MRI L110 or Accolade MRI L310, Boston Scientific)Device

    Dual-chamber cardiac pacemaker (Proponent MRI L211, Proponent MRI L231, Accolade MRI L311 or Accolade MRI L331, Boston Scientific), with rate-adaptive pacing of the right atrium. There will be an associated right atrial lead (INGEVITY™+ MRI pacing lead) and right ventricular lead (INGEVITY™+ MRI pacing lead). Single-chamber cardiac pacemaker (Essentio MRI L110 or Accolade MRI L310, Boston Scientific), with rate-adaptive pacing of the ventricles. There will be an associated right ventricular lead (INGEVITY™+ MRI pacing lead).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Peak oxygen uptakeTime frame: 3 months after the pacemarker stimulation

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hospital Clínico de la Comunidad Valenciana

    Valencia, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.